Novo Nordisk A/S $NVO Position Lessened by W.G. Shaheen & Associates DBA Whitney & Co

Posted by Brian Himes on Jul 17th, 2026

W.G. Shaheen & Associates DBA Whitney & Co decreased its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 90.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,305 shares of the company’s stock after selling 237,478 shares during the period. W.G. Shaheen & Associates DBA Whitney & Co’s holdings in Novo Nordisk A/S were worth $930,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVO. Godfrey Financial Associates Inc. purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $25,000. WealthCollab LLC lifted its holdings in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. Maseco LLP bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: The European Commission approved Novo Nordisk’s once-daily oral Wegovy pill for obesity, making it the first GLP-1 tablet cleared for weight management in the EU and expanding the company’s addressable market. Reuters article on EU approval
Positive Sentiment: Multiple reports said the oral Wegovy approval could help Novo Nordisk extend its lead over Eli Lilly in obesity treatment, reinforcing optimism around the company’s long-term growth in diabetes and weight-loss therapies. Pharmaceutical Technology article on competition with Lilly
Positive Sentiment: Analysts and market commentary pointed to improved growth expectations and higher fair value estimates after the approval, signaling that sentiment around Novo’s obesity pipeline has improved. Yahoo Finance article on fair value estimate
Neutral Sentiment: Novo also announced a new Phase 3 heart failure–obesity trial, which supports its cardiometabolic strategy but is still early-stage and unlikely to affect near-term results. TipRanks article on trial update
Negative Sentiment: Separate news that Sun Pharma won approval in South Africa for a generic version of semaglutide highlights ongoing competitive and copycat-drug pressure on Novo Nordisk’s key products. Reuters article on generic Ozempic approval
Negative Sentiment: Zacks Research downgraded Novo Nordisk from hold to strong sell, showing that not all analysts are convinced the stock’s recent strength will continue. Tickerreport article on downgrade

Novo Nordisk A/S Stock Up 1.9%

NVO opened at $51.50 on Friday. The business has a 50 day moving average price of $46.01 and a 200 day moving average price of $45.79. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $71.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm has a market cap of $229.96 billion, a P/E ratio of 12.09, a price-to-earnings-growth ratio of 4.61 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion during the quarter. Research analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on NVO shares. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Finally, Wolfe Research started coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $65.56.

View Our Latest Report on Novo Nordisk A/S

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.